According to the Xintiandi announcement, the company recently received the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” for the active ingredient fondazepam decanoate approved and issued by the State Drug Administration. The API complies with the requirements relating to drug registration and has been approved for registration. The notice is valid until September 28, 2031. Fondazepam is an artificially synthesized selective coagulation factor Xa inhibitor that can be used to prevent venous thromboembolism and anticoagulant treatment such as deep vein thrombosis and pulmonary embolism after major orthopedic surgery. This approval will enrich the company's product structure and enhance market competitiveness. There is uncertainty about the subsequent production and sale of drugs. Investors are kindly requested to pay attention to investment risks.

According to the Xintiandi announcement, the company recently received the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” for the active ingredient fondazepam decanoate approved and issued by the State Drug Administration. The API complies with the requirements relating to drug registration and has been approved for registration. The notice is valid until September 28, 2031. Fondazepam is an artificially synthesized selective coagulation factor Xa inhibitor that can be used to prevent venous thromboembolism and anticoagulant treatment such as deep vein thrombosis and pulmonary embolism after major orthopedic surgery. This approval will enrich the company's product structure and enhance market competitiveness. There is uncertainty about the subsequent production and sale of drugs. Investors are kindly requested to pay attention to investment risks.